Maxwell Douglas Coll, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mucin-1 | 3 | 2017 | 538 | 0.290 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2024 | 79 | 0.230 |
Why?
|
| Inappropriate Prescribing | 1 | 2024 | 213 | 0.190 |
Why?
|
| Radial Artery | 1 | 2017 | 188 | 0.130 |
Why?
|
| Brachial Artery | 1 | 2017 | 373 | 0.130 |
Why?
|
| Internship and Residency | 3 | 2024 | 5949 | 0.120 |
Why?
|
| Heart Arrest | 1 | 2024 | 1516 | 0.120 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2017 | 291 | 0.110 |
Why?
|
| Vascular Patency | 1 | 2017 | 916 | 0.110 |
Why?
|
| Veins | 1 | 2017 | 768 | 0.110 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 210 | 0.100 |
Why?
|
| Cell Communication | 2 | 2017 | 1660 | 0.100 |
Why?
|
| Upper Extremity | 1 | 2017 | 684 | 0.100 |
Why?
|
| Stromal Cells | 1 | 2017 | 1337 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2017 | 3620 | 0.090 |
Why?
|
| Remission Induction | 1 | 2016 | 2407 | 0.090 |
Why?
|
| Students, Medical | 1 | 2024 | 1964 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2017 | 10478 | 0.090 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 1042 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2017 | 1802 | 0.070 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2017 | 1459 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2017 | 2929 | 0.070 |
Why?
|
| Vaccination | 1 | 2016 | 3431 | 0.060 |
Why?
|
| Physicians | 1 | 2022 | 4614 | 0.060 |
Why?
|
| Peptides | 1 | 2015 | 4353 | 0.050 |
Why?
|
| Coculture Techniques | 2 | 2017 | 1342 | 0.050 |
Why?
|
| Medical Staff, Hospital | 1 | 2024 | 603 | 0.040 |
Why?
|
| Apoptosis | 1 | 2015 | 9516 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 5192 | 0.040 |
Why?
|
| Peer Group | 1 | 2024 | 698 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 2024 | 1139 | 0.040 |
Why?
|
| Focus Groups | 1 | 2024 | 1453 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 1188 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 5857 | 0.030 |
Why?
|
| Aneurysm, False | 1 | 2017 | 263 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 1673 | 0.030 |
Why?
|
| NADP | 1 | 2015 | 230 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2017 | 538 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2017 | 1502 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2017 | 560 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2017 | 1376 | 0.030 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2015 | 413 | 0.030 |
Why?
|
| Edema | 1 | 2017 | 766 | 0.030 |
Why?
|
| Glutathione | 1 | 2015 | 585 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 875 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1705 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 1019 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 998 | 0.020 |
Why?
|
| Immune System | 1 | 2016 | 801 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 3438 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2022 | 3131 | 0.020 |
Why?
|
| Necrosis | 1 | 2015 | 1621 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 1839 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2024 | 8731 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2017 | 1503 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 17135 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2015 | 2632 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 1855 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 1151 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2016 | 1999 | 0.020 |
Why?
|
| Ischemia | 1 | 2017 | 1900 | 0.020 |
Why?
|
| Decision Making | 1 | 2022 | 3953 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2024 | 4848 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4588 | 0.020 |
Why?
|
| Communication | 1 | 2022 | 3912 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 5037 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 6132 | 0.020 |
Why?
|
| Humans | 9 | 2024 | 768393 | 0.020 |
Why?
|
| Female | 6 | 2024 | 397089 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 2146 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 3617 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6541 | 0.020 |
Why?
|
| Male | 5 | 2024 | 364902 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2890 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 5900 | 0.010 |
Why?
|
| Gene Expression | 1 | 2017 | 7598 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2015 | 3139 | 0.010 |
Why?
|
| Hospitalization | 1 | 2024 | 10844 | 0.010 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 13697 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 3112 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2017 | 23631 | 0.010 |
Why?
|
| Aged | 3 | 2024 | 171562 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 12558 | 0.010 |
Why?
|
| Cytokines | 1 | 2017 | 7445 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 5336 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2017 | 8075 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2017 | 3804 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2017 | 65379 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2015 | 12805 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 10267 | 0.010 |
Why?
|
| Mice | 2 | 2017 | 82017 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2015 | 22296 | 0.010 |
Why?
|
| Adult | 2 | 2024 | 223640 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 40272 | 0.010 |
Why?
|
| Animals | 2 | 2017 | 169337 | 0.010 |
Why?
|
| Middle Aged | 2 | 2017 | 223491 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 59686 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 74962 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 81801 | 0.000 |
Why?
|